Tongue and teeth hyperpigmentation in etoposide, prednisolone, vincristine, and cyclophosphamide regimen in the treatment of cutaneous lymphoma.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
Works matching DE "ETOPOSIDE"
Results: 1806
1
2
Effect of lithium chloride and antineoplastic drugs on survival and cell cycle of androgen-dependent prostate cancer LNCap cells.
- Published in:
- Indian Journal of Pharmacology, 2012, v. 44, n. 6, p. 714, doi. 10.4103/0253-7613.103265
- By:
- Publication type:
- Article
3
Protein kinase C stabilizes X-linked inhibitor of apoptosis protein (XIAP) through phosphorylation at Ser.
- Published in:
- Psychogeriatrics, 2011, v. 11, n. 2, p. 90, doi. 10.1111/j.1479-8301.2011.00355.x
- By:
- Publication type:
- Article
4
Growing teratoma syndrome: Brief communication and algorithm for management.
- Published in:
- Australian & New Zealand Journal of Obstetrics & Gynaecology, 2013, v. 53, n. 3, p. 318, doi. 10.1111/ajo.12084
- By:
- Publication type:
- Article
5
Flow cytometric fluorescence pulse width analysis of etoposide-induced nuclear enlargement in HCT116 cells.
- Published in:
- Biotechnology Letters, 2010, v. 32, n. 8, p. 1045, doi. 10.1007/s10529-010-0277-x
- By:
- Publication type:
- Article
6
Two cycles of adjuvant carboplatin in stage I seminoma: 8-year experience by the Hellenic Cooperative Oncology Group (HECOG).
- Published in:
- World Journal of Urology, 2016, v. 34, n. 6, p. 853, doi. 10.1007/s00345-015-1695-0
- By:
- Publication type:
- Article
7
Chemotherapy for patients with poor prognosis germ cell tumors.
- Published in:
- World Journal of Urology, 2009, v. 27, n. 4, p. 471, doi. 10.1007/s00345-009-0404-2
- By:
- Publication type:
- Article
8
Good-risk-advanced germ cell tumors: historical perspective and current standards of care.
- Published in:
- World Journal of Urology, 2009, v. 27, n. 4, p. 463, doi. 10.1007/s00345-009-0431-z
- By:
- Publication type:
- Article
9
Thalidomide potentiates etoposide-induced apoptosis in murine neuroblastoma through suppression of NF-κB activation.
- Published in:
- 2018
- By:
- Publication type:
- journal article
10
Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT.
- Published in:
- 2011
- By:
- Publication type:
- journal article
11
Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration.
- Published in:
- Naunyn-Schmiedeberg's Archives of Pharmacology, 2002, v. 366, n. 3, p. 218, doi. 10.1007/s00210-002-0594-2
- By:
- Publication type:
- Article
12
Old drugs still work! Oral etoposide in a relapsed medulloblastoma.
- Published in:
- Child's Nervous System, 2019, v. 35, n. 5, p. 865, doi. 10.1007/s00381-019-04072-9
- By:
- Publication type:
- Article
13
Treatment outcome and patterns of failure in patients of pinealoblastoma: review of literature and clinical experience from a regional cancer centre in north India.
- Published in:
- Child's Nervous System, 2015, v. 31, n. 8, p. 1291, doi. 10.1007/s00381-015-2751-1
- By:
- Publication type:
- Article
14
Doxorubicin and ifosfamide for high-grade sarcoma during pregnancy.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 2, p. 357, doi. 10.1007/s00280-011-1707-8
- By:
- Publication type:
- Article
15
Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 2, p. 397, doi. 10.1007/s00280-011-1706-9
- By:
- Publication type:
- Article
16
Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 68, n. 4, p. 1027, doi. 10.1007/s00280-011-1576-1
- By:
- Publication type:
- Article
17
Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 68, n. 1, p. 63, doi. 10.1007/s00280-010-1427-5
- By:
- Publication type:
- Article
18
Sensitivity and gene expression profile of fresh human acute myeloid leukemia cells exposed ex vivo to AS602868.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 68, n. 1, p. 97, doi. 10.1007/s00280-010-1458-y
- By:
- Publication type:
- Article
19
Wogonin potentiates the antitumor action of etoposide and ameliorates its adverse effects.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 5, p. 1063, doi. 10.1007/s00280-010-1396-8
- By:
- Publication type:
- Article
20
Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 3, p. 597, doi. 10.1007/s00280-010-1357-2
- By:
- Publication type:
- Article
21
The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2010, v. 66, n. 5, p. 869, doi. 10.1007/s00280-009-1232-1
- By:
- Publication type:
- Article
22
Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant BCR-ABL-positive cells.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2010, v. 66, n. 2, p. 255, doi. 10.1007/s00280-009-1158-7
- By:
- Publication type:
- Article
23
“Metronomic” chemotherapy in advanced soft tissue sarcomas.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2010, v. 66, n. 1, p. 197, doi. 10.1007/s00280-010-1275-3
- By:
- Publication type:
- Article
24
Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 6, p. 1057, doi. 10.1007/s00280-009-1111-9
- By:
- Publication type:
- Article
25
Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 5, p. 839, doi. 10.1007/s00280-009-1089-3
- By:
- Publication type:
- Article
26
Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 65, n. 1, p. 5, doi. 10.1007/s00280-009-0997-6
- By:
- Publication type:
- Article
27
Protection of mouse bone marrow from etoposide-induced genomic damage by dexrazoxane.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 4, p. 837, doi. 10.1007/s00280-009-0934-8
- By:
- Publication type:
- Article
28
A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin’s lymphoma.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 1, p. 27, doi. 10.1007/s00280-008-0847-y
- By:
- Publication type:
- Article
29
Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2008, v. 61, n. 5, p. 785, doi. 10.1007/s00280-007-0535-3
- By:
- Publication type:
- Article
30
A case of mixed adult Wilms’ tumour and angiosarcoma responsive to carboplatin, etoposide and vincristine (CEO ).
- Published in:
- Cancer Chemotherapy & Pharmacology, 2008, v. 61, n. 4, p. 717, doi. 10.1007/s00280-007-0529-1
- By:
- Publication type:
- Article
31
Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2008, v. 61, n. 2, p. 309, doi. 10.1007/s00280-007-0505-9
- By:
- Publication type:
- Article
32
The role of cordycepin in cancer treatment via induction or inhibition of apoptosis: implication of polyadenylation in a cell type specific manner.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2008, v. 61, n. 2, p. 251, doi. 10.1007/s00280-007-0467-y
- By:
- Publication type:
- Article
33
A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
- Published in:
- 2007
- By:
- Publication type:
- journal article
34
Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2007, v. 59, n. 2, p. 275, doi. 10.1007/s00280-006-0269-7
- By:
- Publication type:
- Article
35
A phase I trial of carboplatin and etoposide for elderly (≥75 year-old) patients with small-cell lung cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2006, v. 58, n. 5, p. 601, doi. 10.1007/s00280-006-0188-7
- By:
- Publication type:
- Article
36
Biliary excretion of etoposide in children with cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2006, v. 58, n. 3, p. 415, doi. 10.1007/s00280-005-0180-7
- By:
- Publication type:
- Article
37
CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2006, v. 58, n. 1, p. 35, doi. 10.1007/s00280-005-0136-y
- By:
- Publication type:
- Article
38
Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer.
- Published in:
- 2005
- By:
- Publication type:
- journal article
39
Particular cutaneous side effects with etoposide-containing courses: is VP16 or etoposide phosphate responsible?
- Published in:
- Cancer Chemotherapy & Pharmacology, 2005, v. 55, n. 3, p. 244, doi. 10.1007/s00280-004-0858-2
- By:
- Publication type:
- Article
40
Effect of cyclosporine A on the tissue distribution and pharmacokinetics of etoposide.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2004, v. 54, n. 2, p. 153, doi. 10.1007/s00280-004-0784-3
- By:
- Publication type:
- Article
41
Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2004, v. 53, n. 6, p. 468, doi. 10.1007/s00280-003-0758-x
- By:
- Publication type:
- Article
42
Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2004, v. 53, n. 1, p. 91, doi. 10.1007/s00280-003-0711-z
- By:
- Publication type:
- Article
43
Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2003, v. 52, n. 2, p. 167
- By:
- Publication type:
- Article
44
The schedule-dependent effects of etoposide in leukaemic cell lines: a function of concentration and duration.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2003, v. 51, n. 4, p. 291, doi. 10.1007/s00280-003-0579-y
- By:
- Publication type:
- Article
45
Establishment and characterization of a mouse FM3A cell mutant resistant to topoisomerase II-inhibitor NC-190.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2002, v. 50, n. 5, p. 367, doi. 10.1007/s00280-002-0508-5
- By:
- Publication type:
- Article
46
Topotecan-induced topoisomerase IIα expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2002, v. 49, n. 5, p. 347, doi. 10.1007/s00280-002-0423-9
- By:
- Publication type:
- Article
47
Low dose–high dose: what is the right dose? Pharmacokinetic modeling of etoposide.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2002, v. 49, n. 4, p. 303, doi. 10.1007/s00280-001-0418-y
- By:
- Publication type:
- Article
48
Etoposide induction of tumor immunity in Lewis lung cancer.
- Published in:
- 2001
- By:
- Publication type:
- journal article
49
Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice.
- Published in:
- 2001
- By:
- Publication type:
- journal article
50
Bioequivalence investigation of high-dose etoposide and etoposide phosphate in lymphoma patients.
- Published in:
- 2001
- By:
- Publication type:
- journal article